The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload

A L Sverdlov, D T M Ngo, A K Nightingale, S Rajendran, K Mishra, T Heresztyn, R H Ritchie, T H Marwick, M P Frenneaux, J D Horowitz

Research output: Contribution to journal › Article

8 Citations (Scopus)

Abstract

Nitric oxide (NO) is a modulator of left ventricular hypertrophy (LVH) and myocardial relaxation. The impact of NO availability on development of LVH has never been demonstrated in humans. We tested the hypotheses that elevation of asymmetric dimethylarginine (ADMA) concentrations (biochemical marker of decreased NO generation), and impairment of vascular responsiveness to NO donor GTN, would each predict the presence of LVH and associated LV diastolic dysfunction in a normal aging population.
Original languageEnglish
Pages (from-to)41-46
Number of pages6
JournalNitric Oxide: Biology and Chemistry
Volume25
Issue number1
DOIs
Publication statusPublished - 30 Jun 2011

Fingerprint

Left Ventricular Hypertrophy
Nitric Oxide
Nitric Oxide Donors
Modulators
Blood Vessels
Aging of materials
Biomarkers
Availability
Population
N,N-dimethylarginine

Keywords

  • left ventricular mass
  • nitric oxide
  • vascular function
  • diastolic function
  • asymmetric dimethylarginine

Cite this

Sverdlov, A. L., Ngo, D. T. M., Nightingale, A. K., Rajendran, S., Mishra, K., Heresztyn, T., ... Horowitz, J. D. (2011). The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload. Nitric Oxide: Biology and Chemistry, 25(1), 41-46. https://doi.org/10.1016/j.niox.2011.04.009

The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload. / Sverdlov, A L; Ngo, D T M; Nightingale, A K; Rajendran, S; Mishra, K; Heresztyn, T; Ritchie, R H; Marwick, T H; Frenneaux, M P; Horowitz, J D.

In: Nitric Oxide: Biology and Chemistry, Vol. 25, No. 1, 30.06.2011, p. 41-46.

Research output: Contribution to journal › Article

Sverdlov, AL, Ngo, DTM, Nightingale, AK, Rajendran, S, Mishra, K, Heresztyn, T, Ritchie, RH, Marwick, TH, Frenneaux, MP & Horowitz, JD 2011, 'The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload', Nitric Oxide: Biology and Chemistry, vol. 25, no. 1, pp. 41-46. https://doi.org/10.1016/j.niox.2011.04.009
Sverdlov AL, Ngo DTM, Nightingale AK, Rajendran S, Mishra K, Heresztyn T et al. The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload. Nitric Oxide: Biology and Chemistry. 2011 Jun 30;25(1):41-46. https://doi.org/10.1016/j.niox.2011.04.009
Sverdlov, A L ; Ngo, D T M ; Nightingale, A K ; Rajendran, S ; Mishra, K ; Heresztyn, T ; Ritchie, R H ; Marwick, T H ; Frenneaux, M P ; Horowitz, J D. / The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload. In: Nitric Oxide: Biology and Chemistry. 2011 ; Vol. 25, No. 1. pp. 41-46.
@article{b3da47ebc0fb4155a01912b60aa4c48b,
title = "The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload",
abstract = "Nitric oxide (NO) is a modulator of left ventricular hypertrophy (LVH) and myocardial relaxation. The impact of NO availability on development of LVH has never been demonstrated in humans. We tested the hypotheses that elevation of asymmetric dimethylarginine (ADMA) concentrations (biochemical marker of decreased NO generation), and impairment of vascular responsiveness to NO donor GTN, would each predict the presence of LVH and associated LV diastolic dysfunction in a normal aging population.",
keywords = "left ventricular mass, nitric oxide, vascular function, diastolic function, asymmetric dimethylarginine",
author = "Sverdlov, {A L} and Ngo, {D T M} and Nightingale, {A K} and S Rajendran and K Mishra and T Heresztyn and Ritchie, {R H} and Marwick, {T H} and Frenneaux, {M P} and Horowitz, {J D}",
note = "Copyright {\circledC} 2011. Published by Elsevier Inc.",
year = "2011",
month = "6",
day = "30",
doi = "10.1016/j.niox.2011.04.009",
language = "English",
volume = "25",
pages = "41--46",
journal = "Nitric Oxide: Biology and Chemistry",
issn = "1089-8603",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload

AU - Sverdlov, A L

AU - Ngo, D T M

AU - Nightingale, A K

AU - Rajendran, S

AU - Mishra, K

AU - Heresztyn, T

AU - Ritchie, R H

AU - Marwick, T H

AU - Frenneaux, M P

AU - Horowitz, J D

N1 - Copyright © 2011. Published by Elsevier Inc.

PY - 2011/6/30

Y1 - 2011/6/30

N2 - Nitric oxide (NO) is a modulator of left ventricular hypertrophy (LVH) and myocardial relaxation. The impact of NO availability on development of LVH has never been demonstrated in humans. We tested the hypotheses that elevation of asymmetric dimethylarginine (ADMA) concentrations (biochemical marker of decreased NO generation), and impairment of vascular responsiveness to NO donor GTN, would each predict the presence of LVH and associated LV diastolic dysfunction in a normal aging population.

AB - Nitric oxide (NO) is a modulator of left ventricular hypertrophy (LVH) and myocardial relaxation. The impact of NO availability on development of LVH has never been demonstrated in humans. We tested the hypotheses that elevation of asymmetric dimethylarginine (ADMA) concentrations (biochemical marker of decreased NO generation), and impairment of vascular responsiveness to NO donor GTN, would each predict the presence of LVH and associated LV diastolic dysfunction in a normal aging population.

KW - left ventricular mass

KW - nitric oxide

KW - vascular function

KW - diastolic function

KW - asymmetric dimethylarginine

U2 - 10.1016/j.niox.2011.04.009

DO - 10.1016/j.niox.2011.04.009

M3 - Article

VL - 25

SP - 41

EP - 46

JO - Nitric Oxide: Biology and Chemistry

JF - Nitric Oxide: Biology and Chemistry

SN - 1089-8603

IS - 1

ER -

Access to Document